Stoke Therapeutics, Inc.
Clinical trials sponsored by Stoke Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing RNA-based therapies for genetic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with severe epilepsy: drug trial targets seizures Results expected Mar 2027 (estimated) May already have reported ↗ 🚀 Make-or-break